Filing Flows › Recursion Pharmaceuticals (RXRX) › Q2 2026
Recursion Pharmaceuticals (RXRX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Recursion Pharmaceuticals (RXRX) reported revenue of $7.7M for the second quarter 2026 (Q2 2026), -60% from a year earlier and +19% from the quarter before.
Recursion Pharmaceuticals, Q2 2026: revenue $7.7M (-60% year over year), net loss $131M, operating cash flow −$106M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.7M | +19% | -60% |
| Operating profit | −$135M | — | — |
| Net earnings | −$131M | — | — |
| Operating cash flow | −$106M | — | — |
What changed
Revenue was $7.7M in Q2 2026, down 60% year over year and up 19% from the previous quarter. Operating revenue was the largest line at 95% of revenue. Operating revenue lost $11.8M year over year (down 62%), 102% of the total change.
Operating costs exceeded revenue by $135.0M, an operating margin of -1759.7%. Total costs fell 27% while revenue fell 60%. The quarter ended with a net loss of $131.0M, wider than the previous quarter's $117.5M loss.
Operating cash flow was −$105.9M. Non-cash charges added back $18.2M of depreciation and amortization and $19.5M of share-based compensation. Working capital and other items used $12.6M. Capital expenditures of $44K exceeded it, leaving free cash flow of −$106.0M.
Questions
What was Recursion Pharmaceuticals' revenue in the second quarter 2026?
Recursion Pharmaceuticals (RXRX) reported revenue of $7.7M for the second quarter 2026 (Q2 2026), -60% from a year earlier and +19% from the quarter before.